Please login to the form below

Not currently logged in
Email:
Password:

Merrimack

This page shows the latest Merrimack news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack

Ipsen buys cancer business from stripped down Merrimack. Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval. ... French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by

Latest news

  • Daiichi pulls study of patritumab in lung cancer Daiichi pulls study of patritumab in lung cancer

    Other companies working on HER3 inhibitors include Merrimack Pharma, whose seribantumab (MM-121) candidate is in phase III, as well as GlaxoSmithKline with GKS2849330 (phase I) and Roche's Genentech unit

  • FDA approves Merrimack's pancreatic cancer drug FDA approves Merrimack's pancreatic cancer drug

    The FDA has approved Merrimack's Onivyde for the treatment of advanced pancreatic cancer. ... Biopharmaceutical science company Baxalta has also payed $62.5m to Merrimack as Onviyde enters phase II trials as a first-line treatment for pancreatic cancer

  • Baxter and Merrimack file pancreatic cancer drug in EU Baxter and Merrimack file pancreatic cancer drug in EU

    Baxter and Merrimack file pancreatic cancer drug in EU. MM-398 is thought to help direct the active drug into tumours. ... The FDA has already given the drug priority review status and Merrimack and Baxter, raising the possibility of approval before the

  • Global pancreatic cancer market to treble in value Global pancreatic cancer market to treble in value

    Other drugs marked out by GlobalData as having significant sales potential include Threshold Pharmaceuticals/Merck's TH-302 and Merrimack Pharmaceuticals' MM-398.

  • Eastern Europe targeted

    260. PharmaEngine/Merrimack. MM398 in oncology. Licence. 220. CytRx/Orphazyme. Molecular chaperone assets for rare genetic lysosomal diseases.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    At the start of this year it acquired Merrimack’s oncology business, including Onivyde (liposomal irinotecan), for $575m. ... Also on Ipsen’s radar are opportunities in pancreatic cancer, where it’s keen to maintain the momentum gained from

  • Deal Watch January 2017 Deal Watch January 2017

    Biogen. Patent settlement. Tecfidera (dimethyl fumarate). 1, 250. Merrimack Pharamceuti-cals. Ipsen.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    Three women's health products . 1, 025. 82. Merrimack / Baxter. Licence to commercialise.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Baxter is licensing Merrimack's nanoliposomal injection of irinotecan which has orphan status in the US and the EU for metastatic pancreatic cancer, but does not have US rights.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics